Good morning :)
$
₹
Johnson & Johnson

Johnson & Johnson

JNJ

NYSE
Asset Logo

Johnson & Johnson

JNJ

NYSE
$272.421.41% (-3.89)
$
₹
$272.421.41% (-3.89)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - General

Mega Cap

With a market cap of $640.8B the stock is ranked 22

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

40.39
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

7.98
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$6.59
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

3.04
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

16.2%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

1.95%

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 23 analysts reports

Buy
16 analysts
Hold
6 analysts
Sell
1 analyst

Price Upside

+2.6%

Earnings Growth

+2.96%

Rev. Growth

+7.46%

See Detailed Forecast

Company Profile

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
45.78
45.78
1Y Return
47.62%
47.62%
Buy Reco %
83.87
83.87
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
149.14
149.14
1Y Return
74.12%
74.12%
Buy Reco %
67.85
67.85
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
30.39
30.39
1Y Return
29.02%
29.02%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
26.00
26.00
1Y Return
14.37%
14.37%
Buy Reco %
75.00
75.00
Novo Nordisk A/S
NVO
Novo Nordisk A/S
P/E Ratio
9.89
9.89
1Y Return
16.83%
16.83%
Buy Reco %
21.42
21.42
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 2.60% growth, versus a trailing 3-year CAGR of 24.37%.

2026
Current$272.32Baseline
Analyst Target - 1 year
Target$279.41+2.6%

All values in $

202220232024202520262027$171.56$216.82$262.09Target+2.6%
2026
Current$272.32Baseline
Analyst Target - 1 year
Target$279.41+2.6%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 7.46% growth, versus a trailing 3-year CAGR of 5.60%.

2025
Current$94.19Baseline
Forecast for Dec 2026
High$101.46+7.72%
Average$101.22+7.46%
Low$101+7.23%

All values in $ Billion

20212022202320242025202678.7479.9985.1588.8294.19Low+7.23%Average+7.46%High+7.72%
2025
Current$94.19Baseline
Forecast for Dec 2026
High$101.46+7.72%
Average$101.22+7.46%
Low$101+7.23%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Higher earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 2.96% growth, versus a trailing 3-year CAGR of 2.06%.

2025
Current$10.8Baseline
Forecast for Dec 2026
High$11.28+4.44%
Average$11.12+2.96%
Low$11.05+2.31%

All values in $

2021202220232024202520269.810.1610.439.9910.8Low+2.31%Average+2.96%High+4.44%
2025
Current$10.8Baseline
Forecast for Dec 2026
High$11.28+4.44%
Average$11.12+2.96%
Low$11.05+2.31%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

24.5
5.1
24
5.2
25.3
5.5
25.3
0.2
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue22.4422.4722.5221.8923.7423.9924.5624.0625.3125.39
Net Income4.682.693.4310.995.535.155.115.235.530.21
Net Profit Margin20.87%11.98%15.23%50.23%23.32%21.47%20.82%21.75%21.86%0.82%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - General

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Johnson & Johnson 40.397.983.04
Eli Lilly and Company45.7831.351.35
Merck & Company Inc149.148.722.79
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare JNJ with any stock or ETF
Compare JNJ with any stock or ETF
Comparing from
JNJ
LLY
MRK
Loading...

Frequently asked questions

  1. Johnson & Johnson (JNJ) share price today is $272.42 as of November 6, 2026 at 2:29 AM IST. The stock touched a day high of $281.80 and a day low of $271.80.

  2. Johnson & Johnson stock trades on NYSE under the ticker symbol JNJ.

  3. Johnson & Johnson's market capitalization is $640.75B as of November 6, 2026 at 2:29 AM IST.

  4. Johnson & Johnson's price-to-earnings (P/E) ratio is 40.39 as of November 5, 2026.

  5. Johnson & Johnson's price-to-book (P/B) ratio is 7.98 as of November 5, 2026.

  6. Yes, Johnson & Johnson pays a dividend, with a current dividend yield of 1.95%.

  7. Yes, You can buy Johnson & Johnson shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Johnson & Johnson shares in three steps: 1. Search Johnson & Johnson on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Johnson & Johnson trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Johnson & Johnson (JNJ) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0367 shares at the current price of $272.42.

Loading...